1. Home
  2. BEAT vs BYSI Comparison

BEAT vs BYSI Comparison

Compare BEAT & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Heartbeam Inc.

BEAT

Heartbeam Inc.

HOLD

Current Price

$0.28

Market Cap

22.7M

Sector

Technology

ML Signal

HOLD

Logo BeyondSpring Inc.

BYSI

BeyondSpring Inc.

HOLD

Current Price

$0.32

Market Cap

25.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BEAT
BYSI
Founded
2015
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.7M
25.5M
IPO Year
2021
2016

Fundamental Metrics

Financial Performance
Metric
BEAT
BYSI
Price
$0.28
$0.32
Analyst Decision
Buy
Analyst Count
3
0
Target Price
★ $2.13
N/A
AVG Volume (30 Days)
★ 1.1M
129.3K
Earning Date
11-12-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 15.07
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$49.96
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.30
$0.42
52 Week High
$4.00
$2.44

Technical Indicators

Market Signals
Indicator
BEAT
BYSI
Relative Strength Index (RSI) 30.83 31.34
Support Level N/A N/A
Resistance Level $0.52 $0.80
Average True Range (ATR) 0.03 0.10
MACD -0.01 -0.02
Stochastic Oscillator 3.35 0.91

Price Performance

Historical Comparison
BEAT
BYSI

About BEAT Heartbeam Inc.

HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company's proprietary and patented technology platform captures the heart's electrical activity from three dimensions and synthesizes a 12-lead ECG from these signals. The company has received U.S. Food and Drug Administration (FDA) clearance for its ECG solutions.

About BYSI BeyondSpring Inc.

BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.

Share on Social Networks: